Edition:
United States

Pharming Group NV (PHGUF.PK)

PHGUF.PK on OTC Markets Group - US Other OTC and Grey Market

0.75USD
--
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.75
Open
--
Day's High
--
Day's Low
--
Volume
5
Avg. Vol
232,354
52-wk High
$0.75
52-wk Low
$0.22

Chart for

About

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 80.89 16.34
EPS (TTM): -- -- --
ROI: -- 3.08 14.66
ROE: -- 4.82 14.00

BRIEF-Pharming announces conclusion of FDA end of phase 2 interactions on Ruconest

* PHARMING ANNOUNCES CONCLUSION OF FDA END OF PHASE 2 INTERACTIONS ON RUCONEST FOR PROPHYLAXIS OF HAE

Sep 11 2017

BRIEF-Pharming Group announces cashless warrant exercises and conversions of its ordinary bonds into shares

* ANNOUNCES CASHLESS WARRANT EXERCISES AND CONVERSIONS OF ITS ORDINARY BONDS INTO SHARES

Aug 10 2017

BRIEF-Pharming Group H1 net loss widens to 30.2 million euros

* SAID ON THURSDAY THAT REVENUES FROM PRODUCT SALES FOR THE HALF YEAR INCREASED BY 617 PCT TO EUR 30.1 MILLION (HY 2016: EUR 4.2 MILLION)

Jul 27 2017

BRIEF-Pharming announces publication of Ruconest prophylactic data in The Lancet

* PHARMING ANNOUNCES PUBLICATION OF RUCONEST PROPHYLACTIC DATA IN THE LANCET Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 26 2017

BRIEF-Pharming group announces completion of replacement of its 100 million dollars bridge finance

* ANNOUNCES THAT IT HAS COMPLETED REPLACEMENT OF ITS RECENTLY ANNOUNCED US$100 MILLION BRIDGE FINANCE WITH ORBIMED ADVISORS

Jul 21 2017

BRIEF-Pharming withdraws items related to amendment of articles of association from AGM agenda

* PHARMING ANNOUNCES WITHDRAWAL OF AGENDA ITEMS RELATED TO AMENDMENT OF THE ARTICLES OF ASSOCIATION FROM AGM AGENDA SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Gdynia Newsroom:)

May 17 2017

BRIEF-Pharming Group Q1 operating result swings to EUR 3.9 mln profit

* Q1 NET PRODUCT SALES INCREASED BY 794% TO €15.2 MILLION (2016: €1.7 MILLION),

May 17 2017

BRIEF-Pharming announces refinancing of its existing debt by single $100 million debt facility on improved commercial terms

* PHARMING ANNOUNCES REFINANCING OF ITS EXISTING DEBT BY A SINGLE US$100 MILLION DEBT FACILITY ON IMPROVED COMMERCIAL TERMS

May 16 2017

Earnings vs. Estimates